Xeris Biopharma Holdings, Inc. Common Stock Profile
About
Xeris Biopharma Holdings is a biopharmaceutical company. It involved in developing and commercializing therapies for patient in endocrinology, neurology and gastroenterology. The company's principal product includes Gvoke(R), a ready-to-use liquid glucagon for the treatment of severe hypoglycemia and Keveyis(R), the first and only FDA-approved therapy for primary periodic paralysis. Xeris Biopharma Holdings, formerly known as Xeris Pharmaceuticals Inc., is headquartered in Chicago, IL.
Info & Links
CEO
John Shannon
Headquarters
1375 West Fulton Street, Suite 1300 Chicago, IL 60607, UNITED STATES
Xeris Biopharma Holdings, Inc. Common Stock Statistics
Valuation Measures
Market Capitalization2
1.28B
Enterprise Value
1.44B
Enterprise Value/EBITDA(ttm)
220.76
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
5.14
Price to Book(mrq)
--
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
82.01%
Operating Margin(ttm)
-10.53%
Profit Margin(ttm)
-13.88%
Return on Equity(ttm)
--
Return on Invested Capital(ttm)
-17.12%
Return on Assets(ttm)
-8.00%
Income Statement
Revenue(ttm)
246.03M
Revenue Per Share(ttm)
1.52
Gross Profit(ttm)
202.33M
EBITDA(ttm)3
6.51M
Net Income Available to Common(ttm)
-32.00M
Diluted EPS(ttm)
-0.21
Share Statistics
Beta (5Y Monthly)
0.12
52-Week Change
182.03%
S&P 500 52-Week Change
16.04%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
161.48M
Dividend Yield
0.00%
Float4
154.12M
% Held by Insiders
4.56%
% Held by Institutions
42.75%
Balance Sheet
Total Cash(mrq)
59.28M
Total Cash Per Share(mrq)
0.37
Total Debt(mrq)
218.63M
Total Debt/Equity(mrq)
-1132.54%
Current Ratio(mrq)
1.95%
Quick Ratio(mrq)
1.24%
Book Value Per Share(mrq)
-0.12
Cash Flow
Operating Cash Flow Per Share(ytd)
-0.06
Free Cash Flow(ytd)
-10.14M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.